Two Sigma Advisers
CYCN icon

Two Sigma Advisers’s Cyclerion Therapeutics CYCN Stock Holding History

Two Sigma Advisers’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,300
Closed -$35.9K – 557
2025
Q4 		$35.9K Buy
+28,300
New +$50.5K ﹤0.01% 2293
2023
Q2 		– Sell
-900
Closed -$7.81K – 2439
2023
Q1 		$7.81K Sell
900
-290
-24% -$3.66K ﹤0.01% 2555
2022
Q4 		$15.6K Sell
1,190
-640
-35% -$7.57K ﹤0.01% 2443
2022
Q3 		$31K Sell
1,830
-3,005
-62% -$51.6K ﹤0.01% 2414
2022
Q2 		$53K Sell
4,835
-5,920
-55% -$84.8K ﹤0.01% 2471
2022
Q1 		$239K Sell
10,755
-15,315
-59% -$369K ﹤0.01% 2324
2021
Q4 		$897K Sell
26,070
-6,315
-19% -$298K ﹤0.01% 1616
2021
Q3 		$1.99M Buy
32,385
+16,060
+98% +$1.05M 0.01% 1259
2021
Q2 		$1.27M Buy
16,325
+7,835
+92% +$491K ﹤0.01% 1526
2021
Q1 		$474K Buy
8,490
+5,660
+200% +$425K ﹤0.01% 2033
2020
Q4 		$173K Buy
+2,830
New +$193K ﹤0.01% 2201

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $1.87B AUM 29.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Advisers's CYCN Position: Q1 2026 in Review

Two Sigma Advisers sold out of Cyclerion Therapeutics (CYCN) in Q1 2026, closing a stake of 28,300 shares — an estimated $35.9K sold.

Two Sigma Advisers first reported a position in CYCN in Q4 2020 and held it in 11 quarters. The position peaked at $1.99M in Q3 2021. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • Two Sigma Advisers reported no remaining Cyclerion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 28,300 Cyclerion Therapeutics shares in Q1 2026, an estimated $35.9K.
  • Two Sigma Advisers first reported a position in Cyclerion Therapeutics in Q4 2020 and held it in 11 quarters.
  • Two Sigma Advisers's Cyclerion Therapeutics position peaked at $1.99M in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.